EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy

Justine Huart, François Jouret

Kidney and Blood Pressure Research · 17.03.2025 · 50 (1) · 267-275

DOI: 10.1159/000545286 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney and Blood Pressure Research, online erschienen am 17.03.2025. Verfasst von Justine Huart und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University of Liège Hospital (ULiège CHU), Liège, Belgium. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Mineralocorticoid Receptor Antagonists, Naphthyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease worldwide. The management of DKD relies on controlling glycemia and blood pressure levels, as well as reducing proteinuria. While the traditional renin-angiotensin-aldosterone system inhibitors (RAASi) and the recently approved type 2 Na+/glucose co-transporter inhibitors (SGLT2i) have significantly improved patient outcomes, residual risks remain unaddressed. Summary: This review explores (1) the mechanisms of action of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (ns-MRA), (2) the evidence of finerenone-induced kidney protection in clinical trials, and (3) the comparative advantages over conventional MRAs. The potential synergy between finerenone and SGLT2i is also addressed, alongside research perspectives and practical considerations for implementation in clinical practice. Key Messages: Finerenone has emerged as a breakthrough therapy in the management of DKD, demonstrating robust nephro- and cardio-protective effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesMineralocorticoid Receptor AntagonistsNaphthyridinesHumansSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

Diabetic nephropathyFinerenoneMineralocorticoid receptor antagonistNon-steroidal structure

Substanzen

Mineralocorticoid Receptor AntagonistsfinerenoneNaphthyridinesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, University of Liège Hospital (ULiège CHU), Liège, Belgium.
  • Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), Metabolism and Cardiovascular Biology, Laboratory of Translational Research in Nephrology, University of Liège, Liège, Belgium.

Zitieren

APA

Huart, J., & Jouret, F. (2025). Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy. Kidney and Blood Pressure Research, 50(1), 267-275. https://doi.org/10.1159/000545286

Vancouver

Huart J, Jouret F. Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy. Kidney and Blood Pressure Research. 2025;50(1):267-275. doi:10.1159/000545286

BibTeX
@article{Huart2025,
  author = {Huart, Justine and Jouret, François},
  title = {Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy},
  journal = {Kidney and Blood Pressure Research},
  year = {2025},
  volume = {50},
  number = {1},
  pages = {267--275},
  doi = {10.1159/000545286}
}
Kostenlos starten →